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Introduction and objectives: Umbilical cord blood stem cell
transplantation (UCB-SCT) is characterized by a slow myeloid
engraftment and a high incidence of graft failure. In this study we
analyze the role of hematopoietic chimerism analysis in predicting
engraftment after UCB-SCT. Patients and methods: 49 patients
(31 male and 18 female) undergoing UCB-SCT with available
DNA from bone marrow (BM) samples early after transplant
(range, 14-19 days), were included in the study. Median age was 32
years (range, 16-67). Conditioning regimen consisted of thiotepa,
busulfan, cyclophosphamide and anti-thymocytic globulin in 42
patients while in the remaining 7 cyclophosphamide was replaced
by ﬂudarabine. Cyclosporine A and prednisone were used for
GVHD prophylaxis. All patients received G-CSF from day 7.
Hematopoietic chimerism was analyzed in BM samples using
PCR-STR techniques. Results: 21 patients had mixed chimerism
early post-transplant. It was only associated to the number of
CD34 cells infused (0.9 vs 1.5  105/kg; P  0.018). The
probability of myeloid engraftment was 95% at day 57. Proba-
bility of engraftment at 3 weeks was lower in patients with early
mixed chimerism (43% vs 75%; P  0.0037), low number of
CD34 cells (37% vs 84%; P  0.0001), low number of CFU
(48% vs 75%; P  0.06), and low number of CD3 cells (50% vs
75%; P 0.04). Multivariate analysis showed that only early mixed
chimerism (P  0.01) and dose of CD34 cells (P  0.03) were
independent risk factors for myeloid engraftment. Taking into
account these variables, the probability of engraftment at 3 weeks
identiﬁed three groups of patients: i) patients with both mixed
chimerism and low number of CD34 cells (probability of en-
graftment 31%); ii) patients with only mixed chimerism or low
number of CD34 cells (probability of engraftment 61%); and iii)
patients with complete donor chimerism and high number of
CD34 cells (probability of engraftment 85%). The incidence of
primary graft failure was 25% in the ﬁrst group and 3% in the
remaining two groups (P  0.04). Four out of 5 graft failures
occurred in patients with early mixed chimerism with the lowest
values of donor chimerism (less than 60%). Conclusions: Early
hematopoietic chimerism correlates with the kinetic of engraft-
ment after UCB-SCT and identiﬁes a group of patients with high
probability of primary graft failure.
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UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FOR 59 PEDI-
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CB is an attractive source for unrelated transplantation of benign
indications because of the faster and potentially better availability
for minorities. Since most patients are young children, cell dosage
is less of a critical limitation; however, most studies still see a cell
dose effect. Two strategies were employed to maximize cell dose
are plasma depletion (PD) rather than red blood cells depletion
during processing, to forego post-thaw wash, and use of double
cords. A retrospective audited analysis was performed on all pedi-
atric patients with benign disorders transplanted with PD CB.
Patients were deﬁned in two different ways: by age (less than 16
years) and by weight (less than 50kg). When age is used, there were
55 pediatric patients transplanted with 55 PD CB units (4 double
cords); and if classiﬁed by weight, there were 57 patients trans-
planted with 64 PD CB units (7 double cords). When either
deﬁnition was used, the diagnoses were: Thalassemia (29), Aplastic
anemia (7), Wiscott Aldrich Syndrome (5), Severe Combined Im-
munodeﬁciency (5), Osteopetrosis (2), Hemophagocytic Lympho-
histiocytosis (2), Hurler’s Syndrome (2), sickle cell disease,
Chronic Granulomatous Disease, Fanconi Anemia, Leroy I-Cell
Disease, Lymphohistiocytosis, unspeciﬁed metabolic disease, and
Alpha Mannosidosis each (1 each). Transplant characteristics of all
59 patients: median age 4.2 years old (range 0.5-27.4); median
weight 16.8 kg (range 5-49); male 57%; median # HLA ABDR
matches of 5.0 (11-6/6; 19-5/6; 20-4/6; 5-3/6, 1-2/6); median
pre-freeze TNC dose 8.1  107/kg; median post-thaw TNC dose
as reported by TC 7.7  107/kg; median pre-freeze CD34 dose
3.1  105/kg; transplants outside of U.S.- 31 (53%); double unit
transplant 12%; non-myeloablative – 9 (15%); 45% post-thaw
washed (W) and 55% infused without post-thaw wash (NW) of
those with known post-thaw status. Median follow-up time was
218 days (range 4-1,100 days). Kaplan-Meier estimates were used
for outcome analysis and all deaths prior to engraftment were
counted as graft failures. Post-thaw wash did not improve the
safety or efﬁcacy of outcome and appear to delay engraftment. This
series is unusual in its cell dose, which is high even for pediatric
patients, and shows that unrelated PD CBT can be performed
safely with outstanding engraftment and overall survival in a di-
verse population of pediatric patients with benign disorders.
Outcome Summary
ANC500 &
median time
Plt 50K &
median time
Autologous
Recovery
Rate
1-Yr
TRM
1-Yr
OS
1-Yr
DFS
Age
<16 yo 865%, 19 days 846%, 60 days 43% 165% 845% 786%
Wt
<50 kg 865%, 20 days 846%, 61 days 43% 185% 825% 776%
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ESTIMATION OF HIGH-RESOLUTION HLA-A*, -B*, -C*, -DRB1* HAP-
LOTYPES AND IMPLICATIONS FOR STEM CELL DONOR REGISTRY
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Knowledge of haplotype frequencies of registered potential stem
cell donors is important for both individual donor searches and
questions of strategic donor registry planning. Most published
analyses are based on HLA-A, -B, -DRB1 haplotypes at low/
intermediate resolution level. However, there has been increasing
evidence over the last years that the HLA-C locus and allele
matching are also of relevance for transplantation success.
The analysis of high-resolution haplotypes from donor registry
data is hampered by the fact that registered donors with high-
resolution HLA results for several loci were often selected for
conﬁrmatory typings or donated stem cells. Therefore, samples
that are created by simply choosing donors with high-resolution
HLA results for deﬁned loci from a given donor pool will poten-
tially be affected by a difﬁcult-to-assess selection bias.
We calculated HLA-A*, -B*, -C*, -DRB1* haplotype frequencies
from 7,905 Caucasian donors. These donors were taken from 7,974
DKMS donors who were fully high-resolution typed by sequence-
based typing (SBT) at recruitment. SBT resulted in 4 (or 6) digit
results or in codes in case of ambiguities outside exon 2 (Class II)
or exons 2 and 3 (Class I). 69 donors were excluded from analysis,
mainly because of ambiguities related to the detection of new
alleles. Calculations were performed using the ARLEQUIN soft-
ware package and standard spreadsheet software.
Under the assumption that donor and patient populations have
same haplotype frequency distributions the calculated values can be
used to estimate the probability to ﬁnd at least one matching donor
for patients in need of a stem cell transplant by donor registry size.
The estimated probabilities are 65.0% and 87.3% for registry
sizes of 106 and 107 donors, respectively. If only HLA-A, -B,
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-DRB1 haplotypes on low/intermediate resolution level are con-
sidered, the corresponding values are 85.0% and 97.2%.
These results quantify the decrease in matching probabilities
through more elaborated matching criteria. Signiﬁcant further
recruitment efforts are necessary to maintain high probabilites to
ﬁnd optimal donors as the criteria for optimal donors become more
demanding.
AUTOLOGOUS TRANSPLANTS
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AMD3100 PLUS G-CSF MOBILIZES THE MAJORITY OF NON-HODGKIN’S
LYMPHOMA (NHL), MULTIPLE MYELOMA (MM), AND HODGKIN’S DIS-
EASE (HD) PATIENTS WHO FAILED PRIOR MOBILIZATION WITH
OTHER REGIMENS
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Crocker, S.-A.1, Badel, K.1 1AnorMED, Langley, BC, Canada; 2BMT
Program - Virginia Commonwealth University, Richmond, VA; 3BMT
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Background: AMD3100, an inhibitor of SDF1 binding to
CXCR4, synergizes with G-CSF to allow mobilization of sufﬁcient
CD34 cells/kg for autologous transplantation in pts unable to
collect adequate CD34 cells with G-CSF alone. A single pt use
(SPU) protocol for AMD3100 was adopted for1 pt entry per site
and termed Compassionate Use Protocol (CUP). The only differ-
ence of standard of care was the addition of AMD3100 to a G-CSF
mobilization on the evening prior to each day of apheresis. Pts who
could not proceed to apheresis due to low peripheral blood counts
or pts who did not collect a minimum of 2  10^6 CD34 cell/kg
were eligible. Methods: Overall, more than 280 patients with
proven poor mobilization including 137 NHL, 73 MM, and 31
HD have been included in CUP. A data audit was performed to
validate data from these pts. Sites were selected based on most
patients entered, 3 of all diseases entered at a site, and sites
conducting an AMD3100 trial. Audit included all pts, regardless of
of the outcome; all information was collected on CRFs. Success of
outcome was collection of 210^6 CD34 cells/kg during the
CUP procedure. CUP apheresis was done on day 5 after G-CSF
(10mg/kg SC QD) and AMD3100 (240mg/kg SC Q10 PM) start-
ing day 4. Results: Charts and CRFs were available for review for
115 pts; 63 (55%) were NHL patients from 29 sites, 35 (30%) were
MM from 23 sites and 17 (15%) were HD from 13 sites. Of these
pts, 58% were male, the median age was 59 yrs (range 21-77), 88%
were Caucasian, and pt weight ranged from 43-128 kg. Prior
treatments included a median of 2 regimens of chemotherapy in
each of the 3 groups. Safety was generally favorable with no
drug-related SAE s and with an AE proﬁle similar to that seen in
research trials. The rates of successful collection of 210^6
CD34 cells/kg per disease state as well as prior mobilization
regimen are summarized in table 1. The median number of mo-
bilizations for the successful patients was 3 days for NHL and HD
and 4 for MM. 88 of the patients underwent transplantation with
any cells; of the 47 NHL patients transplanted, 24 had CUP only
cells and 23 had mixed cells. The median number of days to
engraftment was 11 for PMN and 18 for platelets. Long term
follow up is limited, but there do not appear to be graft failures. At
least 12 of the pts have died. Conclusions: AMD3100 in a poor
mobilizer population is generally safe and well tolerated and is very
effective in mobilizing  210^6 CD34 cells/kg.
Mobilization success rate by disease state: overall and prior
mobilization regimen
Overall Prior Cytokine Prior Chemotherapy
NHL 60% 53% 68%
HD 76% 78% 75%
MM 71% 73% 71%
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KINETICS OF AUTOLOGOUS STEM CELL MOBILIZATION FAILURE: COM-
PARISON OF AMD3100/G-CSF, G-CSF, GM-/G-CSF, AND CHEMOTHER-
APY/G-CSF ON REMOBILIZATION SUCCESS
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Background: No standard approach for the mobilization of
peripheral hematologic stem and progenitor cells (HSPCs) has
been established. High levels of circulating CD34 cells, a
surrogate marker for mobilization efﬁciency, are associated with
less apheresis days. A higher dose of CD34 cell transfused
after high-dose chemotherapy decreases time to hematologic
recovery. Consequently, a better understanding of variables
associated with mobilization kinetics may further optimize stem
cell collection and reduce complications associated with autol-
ogous stem cell transplants. Methods: The Washington Uni-
versity (St. Louis, MO) transplantation database includes clini-
cal parameters from 407 multiple myeloma (MM), 567 non-
Hodgkins Lymphoma (NHL), and 164 Hodgkin s disease (HD)
pts who received an ASCT between 1995 and 2006. A retro-
spective analysis of this large pt population was conducted to
determine factors associated with the mobilization kinetics of
CD34 cells. Results: Table 1 summarizes the mobilization
kinetics as deﬁned by number of days to reach a target of 2 
10^6 CD34 cells/kg. Overall, the median number of aphereses
to reach the target were 1, 2, and 2 in MM, NHL, and HD,
respectively. Daily median CD34 yields in MM pts were 3.8,
1.2, and 0.5  10^6 on day 1-3, respectively. In NHL pts, yields
were 1.4, 0.8, and 0.4  10^6 on day 1-3. In HD pts, yields were
1.8, 0.8, and 0.3  10^6 on day 1-3, respectively. The addition
of chemotherapy increased the % of pts requiring only a single
apheresis to reach the mobilization target. Table 2 summarizes
the mobilization kinetics for each re-mobilization regimen. In
general, a limited number of cells was collected with each
aphereses; 70% of pts failed to mobilize 2  10^6 CD34
cells/kg. In contrast, remobilization with AMD3100 allowed the
collection of sufﬁcient CD34 cells in 67% of pts; median
number of apheresis to reach the target was 3. Conclusions:
Factors associated with mobilization kinetics of CD34 cells
include disease state and mobilization regimen. Re-mobilization
is associated with high failure rates, re-mobilization regimens
including AMD3100 are more successful.
Mobilization kinetics by (1) disease state, and (2) re-mobilization
regimen
Table 1 > 210^6 CD34/kg: Day 1 Day 2 Day 3-5 Failed
MM G-CSF 59.3% 17.9% 16.3% 6.5%
G-CSF/Chemo 88.2% 0% 5.9% 5.9%
NHL G-CSF 29.7% 20.6% 23.2% 26.5%
G-CSF/Chemo 42.9% 22.8% 11.4% 22.9%
HD G-CSF 32.3% 23.9% 17.6% 26.2%
G-CSF/Chemo 33.3% 25.0% 25.0% 16.7%
Table 2 > 210^6 CD34/kg: Day 1 Day 2 Day 3-5 Failed
G-CSF 2.3% 5.7% 6.3% 85.7%
G-CSF/GM 4.8% 7.9% 14.3% 73%
G-CSF/Chemo 4.5% 13.7% 6.8% 75%
AMD3100 12.5% 25.0% 29.5% 33%
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